XTL Biopharmaceuticals Ltd
XTLBNasdaqCIK 1023549Healthcare
Revenue is not reported in this company’s XBRL financial statements.
Latest quarter: not reported
Last eight quarters
Full statements| Line item | Unit | Shape over the periods |
|---|---|---|
| Revenue | $ | |
| Gross margin | % | |
| Operating margin | % | |
| Net margin | % | |
| Diluted EPS | $ per share | |
| Free cash flow | $ |
Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.
Last five fiscal years
| Line item | Unit | FY20202020-12-31 | FY20212021-12-31 | FY20222022-12-31 | FY2023-12-31 | FY20242024-12-31 | Shape over the periods |
|---|---|---|---|---|---|---|---|
| Revenue | $k | not reported (Revenue not reported) | not reported (Revenue not reported) | not reported (Revenue not reported) | not reported (Revenue not reported) | 451Revenue, FY2024, twelve months to 2024-12-31$451.0k. XBRL concept ifrs-full:Revenue. 20-F filed 2025-04-30, accession 0001213900-25-037590.Report this figure | |
| Gross margin | % | not reported (Gross profit and Revenue not reported) | not reported (Gross profit and Revenue not reported) | not reported (Gross profit and Revenue not reported) | not reported (Gross profit and Revenue not reported) | 0.7%Gross margin, FY2024, twelve months to 2024-12-31. gross profit / revenueGross profit: $3.0k. XBRL concept ifrs-full:GrossProfit. 20-F filed 2025-04-30, accession 0001213900-25-037590.Revenue: $451.0k. XBRL concept ifrs-full:Revenue. 20-F filed 2025-04-30, accession 0001213900-25-037590.Report this figure | |
| Operating margin | % | not reported (Revenue not reported) | not reported (Revenue not reported) | not reported (Revenue not reported) | not reported (Revenue not reported) | (481.6%)Operating margin, FY2024, twelve months to 2024-12-31. operating income / revenueOperating income: −$2.2m. XBRL concept ifrs-full:ProfitLossFromOperatingActivities. 20-F filed 2025-04-30, accession 0001213900-25-037590.Revenue: $451.0k. XBRL concept ifrs-full:Revenue. 20-F filed 2025-04-30, accession 0001213900-25-037590.Report this figure | |
| Net margin | % | not reported (Revenue not reported) | not reported (Revenue not reported) | not reported (Revenue not reported) | not reported (Revenue not reported) | (227.7%)Net margin, FY2024, twelve months to 2024-12-31. net income / revenueNet income: −$1.0m. XBRL concept ifrs-full:ProfitLoss. 20-F filed 2025-04-30, accession 0001213900-25-037590.Revenue: $451.0k. XBRL concept ifrs-full:Revenue. 20-F filed 2025-04-30, accession 0001213900-25-037590.Report this figure | |
| Diluted EPS | $ per share | (0.01)Diluted EPS, FY2020, twelve months to 2020-12-31−$0.01 per share. XBRL concept ifrs-full:DilutedEarningsLossPerShare. 20-F filed 2023-03-22, accession 0001213900-23-021869.Report this figure | 0.00Diluted EPS, FY2021, twelve months to 2021-12-31$0.00 per share. XBRL concept ifrs-full:DilutedEarningsLossPerShare. 20-F filed 2023-03-22, accession 0001213900-23-021869.Report this figure | (0.00)Diluted EPS, FY2022, twelve months to 2022-12-31−$0.00 per share. XBRL concept ifrs-full:DilutedEarningsLossPerShare. 20-F filed 2025-04-30, accession 0001213900-25-037590.Report this figure | (0.00)Diluted EPS, period not labelled, twelve months to 2023-12-31−$0.00 per share. XBRL concept ifrs-full:DilutedEarningsLossPerShare. 20-F filed 2025-04-30, accession 0001213900-25-037590.Report this figure | (0.00)Diluted EPS, FY2024, twelve months to 2024-12-31−$0.00 per share. XBRL concept ifrs-full:DilutedEarningsLossPerShare. 20-F filed 2025-04-30, accession 0001213900-25-037590.Report this figure | |
| Free cash flow | $k | (851)Free cash flow, FY2020, twelve months to 2020-12-31. operating cash flow − capital expenditureOperating cash flow: −$850.0k. XBRL concept ifrs-full:CashFlowsFromUsedInOperatingActivities. 20-F filed 2023-03-22, accession 0001213900-23-021869.Capital expenditure: $1.0k. XBRL concept ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities. 20-F filed 2023-03-22, accession 0001213900-23-021869.Report this figure | not reported (Capital expenditure not reported) | not reported (Capital expenditure not reported) | not reported (Capital expenditure not reported) | (1,672)Free cash flow, FY2024, twelve months to 2024-12-31. operating cash flow − capital expenditureOperating cash flow: −$1.6m. XBRL concept ifrs-full:CashFlowsFromUsedInOperatingActivities. 20-F filed 2025-04-30, accession 0001213900-25-037590.Capital expenditure: $54.0k. XBRL concept ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities. 20-F filed 2025-04-30, accession 0001213900-25-037590.Report this figure |
Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.
Insider purchases and sales
All insider transactionsThe last 20 open-market transactions reported on Form 4 (codes P and S). The reported price is the price per share the insider stated on the form: filing data, not a market price.
No open-market purchases or sales by insiders are in coverage from Nov 2024 to Oct 2026.
No open-market purchases or sales by insiders are in coverage for this company.
Funds that report holding it
All fundsFrom each manager's latest Form 13F, largest reported value first. Reported value is as filed at the quarter end: filing data, not a price. A put or call is an option position, not shares held.
| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
|---|---|---|---|---|---|
| RHUMBLINE ADVISERS | 2026-06-30 | $17.0k | 6,228 | Added+241 | |
| GAMMA Investing LLC | 2026-06-30 | $3.3k | 1,213 | Reduced−2,175 | |
| UBS Group AG | 2026-06-30 | $341 | 125 | New+125 |
Recent filings
All 376 filingsReports and events: 10-K, 10-Q, 8-K, proxy statements and ownership schedules.
| Filed | Form | What it is | Accession number |
|---|---|---|---|
| 2026-10-1420:05 ET | 6-K | Report of a foreign private issuerPeriod 2026-10-14 | 0001213900-26-109415 |
| 2026-08-0520:21 ET | 6-K | Report of a foreign private issuerPeriod 2026-08-05 | 0001213900-26-085693 |
| 2026-07-2120:05 ET | 6-K | Report of a foreign private issuerPeriod 2026-07-21 | 0001213900-26-080006 |
| 2026-06-3021:24 ET | 20-F | Annual report of a foreign private issuerPeriod 2025-12-31 | 0001213900-26-073831 |
| 2026-06-3021:16 ET | 6-K | Report of a foreign private issuerPeriod 2026-06-30 | 0001213900-26-073813 |
| 2026-06-2920:39 ET | 6-K | Report of a foreign private issuerPeriod 2026-06-29 | 0001213900-26-073158 |
| 2026-06-2323:23 ET | 6-K | Report of a foreign private issuerPeriod 2026-06-22 | 0001213900-26-070771 |
| 2026-05-2220:11 ET | 6-K | Report of a foreign private issuerPeriod 2026-05-22 | 0001213900-26-060565 |
| 2026-05-1521:09 ET | 6-K | Report of a foreign private issuerPeriod 2026-05-15 | 0001213900-26-057942 |
| 2026-05-0712:10 ET | 6-K | Report of a foreign private issuerPeriod 2026-05-07 | 0001213900-26-053067 |
Latest annual report
Form 20-F for the fiscal year ended Dec 31, 2025Filed Jun 30, 2026. Its page lists the documents and the extracted sections, such as Business and Risk factors.
Forecast league
Not in this season’s league. The league lists companies whose quarter has ended and whose results are not yet filed.This season’s league
About the filer
- CIK
- 1023549
- Tickers
- XTLB
- Exchange
- Nasdaq
- SIC code
- 2834 Pharmaceutical Preparations
- Sector
- Healthcare
- Fiscal year ends
- not reported
- Incorporated in
- L3
- Filer category
- Non-accelerated filer
Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:30 ET. Listed shows no prices and gives no investment advice.